BRNS (Barinthus Biotherapeutics) חוב לטווח קצר להון

Barinthus Biotherapeutics (BRNS) laboratories are currently focused on conducting clinical trials using calibrated equipment and reserved partner capacities. This chart of the market trend in monetary terms shows a debt-to-equity ratio of 0.05, while the business implements energy-saving technologies to minimize its environmental footprint. High barriers to entry are ensured by patents for cancer and hepatitis B therapies under strict FDA and EMA supervision.

This indicator compares liabilities with a maturity of up to one year against net assets, measuring the company's dependence on short-term borrowing. For Barinthus Biotherapeutics (BRNS), which possesses significant pricing power in the immunotherapy segment, analyzing the short-term financial leverage ratio on GURU.Markets allows for an assessment of how effectively the unique ChAdOx platform generates liquidity to service current debts without the risk of capital freezing.